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Seniors Welcome!
Avoiding the Trap of Age Limits in Health Research
Arshad Jahangir, MD │ Message from the Guest Editor
Sheikh Khalifa bin Hamad al Thani Center for Integrative Research on Cardiovascular Aging,
Aurora Research Institute, and Aurora Cardiovascular Services, Aurora Health Care, Milwaukee, WI

This issue of the Journal of Patient-Centered Research
and Reviews covers a contemporary and underreported
area in patient-centered research, that of cardiovascular
diseases in the elderly. With the changing demographics
of the U.S. population toward a larger group of olderage people and the higher prevalence of cardiovascular
diseases in the elderly,1,2 it is important for health care
researchers to concentrate their efforts on insights into
aging-associated diseases, so as to reduce their effect
on overall morbidity and mortality. It is disappointing
that despite the known association of advancing age
with cardiovascular disease and poor clinical outcomes,
little is understood about mechanisms underlying
aging-associated functional decline and factors that
contribute to impaired quality of life, disability and loss
of independence.3
The evidence base to optimally manage cardiovascular
diseases in the older-elderly also is limited due to the
exclusion from or scant representation in randomized
clinical trials of subjects ≥ 75 years of age and those
residing in nursing homes or assisted care facilities.3-6
Even when the elderly have been included in trials,
they were relatively healthy and had few comorbidities,
meaning these subjects were not necessarily
representative of the community.7 Therefore, clinical
decision-making in the older-elderly is based on
extrapolation of data obtained from studies enrolling
younger patients with few comorbidities or minimal
functional limitations, resulting in limited information
about efficacy, safety and cost-effectiveness of
interventions.8,9
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Editorial

As health care costs
continue
to
rise,
resources need to be
directed more efficiently
toward reducing disease
burden and disability by
focusing research efforts
on prevention and early
detection of disease. In
addition,
therapeutic
selection needs to be
based on data that clearly
demonstrate quality- and quantity-of-life benefits as
well as prevention of complications and potential
adverse effects that could arise in the frail elderly due to
the presence of multiple comorbidities, polypharmacy
and altered biology.10-12 A concerted effort by scientists,
physicians and other health care providers is needed to
define basic mechanisms underlying functional decline
and susceptibility to disease with aging and to design
better community-based studies that include a broad
spectrum of elderly patients representative of those seen
in clinical practice, with a focus on clinical outcomes
most relevant for this population, such as functional
independence and quality of life.
To forward this goal, JPCRR presents herein five
articles related to the study of cardiovascular diseases
in the elderly, which we hope provide a foundation
on which researchers throughout the world can build
improved health care models for this vulnerable and
growing patient population.
In a study that used mouse embryonic cell lines,
Negmadjanov et al.13 assess canonical and noncanonical
intracellular pathways involved in TGF-β1-mediated
antagonism of programmed cell death of fibroblasts,
the cells involved in scar formation after injury.14-16
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Since persistence of activated fibroblasts in the heart
after injury can contribute to progressive fibrosis and
promotion of mechanical and electrical dysfunction ––
thereby increasing predisposition to heart failure and
arrhythmias17 –– their findings are of potential clinical
importance. The study’s significance lies in defining the
relative contribution of Smad-dependent and Erk1/2
intracellular signaling in mediation of the profibrotic
effect of TGF-β1, a cytokine that increases during
inflammation, heart failure and other diseased states.
Design of novel strategies may target these pathways
to reduce fibrosis and resultant morbidity seen in agingassociated conditions that promote excessive and
progressive tissue scarring.
Ross and Jahangir18 provide additional insight to this
phenomenon, reviewing the literature on the contribution
of various ion channels expressed on fibroblast cell
membranes in modulating fibroblast function, including
proliferation, differentiation, secretion and apoptosis,
functions important for tissue repair and scar formation
under physiological conditions and their respective
alteration caused by age-related cardiac diseases that
promote excessive fibrosis.16 Understanding the role
of ion channels on cardiac fibroblasts in mediating
their responses to physiological stress and pathological
states may help facilitate the development of novel
therapeutic strategies to limit cardiac fibrosis and its
adverse effect on myocardial function.
Bhandari et al.,19 in an original study using retrospective
data from the National Inpatient Sample, described
in-hospital outcomes of 48,872 patients hospitalized
for acute mesenteric ischemia, which was more often
present in patients with atrial fibrillation than those
without. Patients with atrial fibrillation were more
likely to be admitted emergently, were sicker and
had worse outcomes, including higher in-hospital
mortality. The authors also found that elderly patients
with atrial fibrillation who were on anticoagulation
were less likely to have serious complications from
acute mesenteric ischemia, such as hemodynamic
shock, small bowel resection, colectomy and need
for mechanical ventilation, and had a shorter length
of stay and lower hospital charges than those not on
anticoagulation. This observation is important for the
management of patients at risk for this serious medical
condition that continues to carry high morbidity
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and mortality despite recent advances,20 providing
supportive evidence for the recommendation of chronic
anticoagulation to protect against acute mesenteric
ischemia, similar to what has been validated to reduce
risk of stroke in atrial fibrillation.21 Overall, the
report’s large sample of patients hospitalized for acute
mesenteric ischemia helps fill in existing knowledge
gaps regarding atrial fibrillation, since the relatively
low incidence of this complication has yielded limited
published information.22
In a timely review article, Dang et al.23 provide an
update on stroke in atrial fibrillation, an important
public health issue contributing to disability and death
in elderly patients.1 The authors review pathogenesis
of thromboembolism in atrial fibrillation, define
predisposing clinical characteristics and risk factors for
stroke and summarize select issues in its management,
including the use of novel anticoagulants and
nonpharmacological approaches to reducing stroke
risk in older-age patients with atrial fibrillation. With
the aging of the population and a projected increase
in the prevalence of atrial fibrillation from about 2.3
million Americans to more than 15 million in the next
30 years, this issue cannot be ignored.21,22,24 More than
one-third of patients with atrial fibrillation are greater
than 80 years old, making reducing stroke risk with the
use of anticoagulants without an excessive increase
in serious bleeding risk a major challenge; clinical
management must take into account the overall impact
of age on cardiac structural and functional alterations
along with comorbidities that increase stroke and
bleeding risk as highlighted by the CHA2DS2-VASc
and HAS-BLED risk scoring systems.21 The authors
review challenges in stroke management among
elderly patients with atrial fibrillation and highlight
the need for additional studies to improve predictive
modeling by incorporating clinical information
on renal dysfunction, frailty, and novel biological
and genetic markers to define thromboembolic and
bleeding complication risk and to assess the efficacy
and safety of pharmacological or nonpharmacological
approaches to stroke prevention.3
Another important cardiovascular issue concerning
the growing aging population is the projected rise in
incidence of heart failure to 700,000 cases per year, which
translates into a 46% increase in prevalence within two
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decades.1 Guzman-Gutierrez and colleagues25 provide
an update on treatment options for advanced heart failure
in elderly patients, who are disproportionately affected
by this disease and experience high morbidity and
mortality. Data on improvement in quality and quantity
of life with heart transplantation and left ventricular
assist device therapy and the utility of palliative care
and a social support program for symptom relief is
discussed. With the rapid growth of the older-elderly
(≥ 75 years) population, the efficacy and safety of
mechanical circulatory support for advanced heart
failure as destination therapy in this population needs
to be better defined. Additionally, studies that improve
understanding of mechanisms and define optimal
management for improving survival, hospitalization,
quality of life, functional capacity and cost-effectiveness
in the growing number of elderly with heart failure with
preserved ejection fraction are needed.3
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In some ways, science is a victim of its own success.
We remain grateful for the improvements in health
care that have allowed more humans to live longer.
Unfortunately, this progress means diseases related
to cardiovascular aging threaten to reach epidemic
proportions in the coming decades. Now is the time
to learn as much as we can about the mechanisms
affecting these conditions and to aim at developing
novel therapies that improve patient outcomes.
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